No description available.

No description available.

Neurólises de plexos simpáticos têm sido utilizadas no tratamento da dor oncológica, mostrando ser um recurso terapêutico bastante eficaz e seguro. Alguns estudos apontam a utilização da neurólise de plexos simpáticos em estágios iniciais da doença por prevenir a dor e melhorar a qualidade de vida, contrariando a OMS que preconiza o uso de métodos invasivos em última instância. Em estudo prospectivo, randomizado e controlado, neurólise de plexos simpáticos realizada em estágios diferentes do tratamento da dor oncológica foi comparada com o tratamento farmacológico. Foram selecionados 60 pacientes com câncer abdominal ou pélvico e alocados em três grupos. No grupo I (precoce) os pacientes estavam em uso de AINEs e opióides fracos ou fortes (dose inferior a 90mg/dia de morfina) e reportavam dor (VAS  4) quando foram submetidos a neurólise plexo celíaco (NPC), neurólise do plexo hipogástrico superior (NPHS) ou neurólise plexo simpático lombar (NPSL) de acordo com o sítio de dor. No grupo II (tardio) a neurólise foi realizada quando a utilização de AINEs e morfina foram iguais ou superiores a 90mg/dia de morfina e VAS>4. No grupo III (controle) os pacientes fizeram uso somente de medicação analgésica. Os pacientes foram observados durante 8 semanas e avaliados quanto à intensidade da dor (VAS), consumo de opióides e qualidade de vida. Imediatamente após as neurólises e durante todo o tempo de observação, os pacientes dos grupos precoce e tardio apresentaram redução da intensidade da dor e do consumo de opióides, além disso melhora da qualidade de vida quando comparados com o grupo controle. Não houve diferenças entre os grupos precoce e tardio nestes aspectos. Efeitos adversos correlacionados com o uso de opióide, como náuseas e/ou vômitos, perda do apetite e constipação foram significativamente maiores no grupo controle. Complicações relacionadas às neurólises, tais como hipotensão e diarréia, foram transitórias e não deferiram significativamente do grupo controle. Não foram encontradas complicações sérias em nenhum dos grupos experimentais. A neurólise de plexos simpáticos foi efetiva na redução da intensidade da dor e do consumo de analgésicos e dos efeitos adversos relacionados com a administração de drogas, e na melhora da qualidade de vida dos pacientes. Embora não havendo diferenças entre os grupos precoce e tardio, os resultados apontam a necessidade de utilizar esta técnica como recurso não somente em fase terminal da doença. / Neurolytic sympathetic plexus blocks (NSPB) have been used as a quite effective and safe therapeutic resource for the treatment of cancer pain. Studies point to the use of NSPB in the early phases of the disease to prevent pain and to improve the life quality, contradicting WHO that extols the use of invasive methods ultimately. We compared the use of neurolytic plexus block in two different phases of the treatment of oncology pain with the pharmacological therapy. In prospective study, randomized and controlled, sixty patients with abdominal or pelvic oncology pain were allocated to tree groups. In group I (early block) the patients using NSAID and weak opioid or oral morphine at a dose of less than 90 mg/day and reporting pain (VAS  4) were submitted to a neurolytic celiac plexus block (NCPB), superior hypogastric plexus block (SHPB) or lumbar sympathetic ganglionic chain (LSGCB), in accordance to the site of pain. In group 2 (late block) the patients were submitted neurolysis when using NSAID and oral morphine at a dose equals to or more than 90 mg/day and VAS  4. In group 3 (control), patients were treated with pharmacological therapy only. The patients were observed for 8 weeks and appraised for the intensity of the pain (VAS), opioid consumption and quality of live. The patients of groups I and II had reduction of the intensity of the pain, opioid consumption and get better quality of live immediately after to the neurolytic and during the whole time of observation when compared with the group control. There were no significant differences between groups I and II with these aspects. Adverse effects correlated with the use of opioids, as nauseas and/or vomits, loss of the appetite and constipation were significantly larger in the group control. Neurolysis related complications such as hypotension and diarrhea, were transitory and statistically similar to these found in the control group. They were not found serious complications. The neurolysis of sympathetic plexus was shown to be effective to reduce the intensity of pain, analgesic consumption and adverse effects related to the use of opioids, and in the improvement of the quality of life. The results point to the usefulness of indicating neurolytic procedure for the management of cancer pain not only in terminal phase of the disease.

É hipótese que (treinamento) T iniciado na fase pré-hipertensiva possa reduzir a atividade simpática e aumentar a vagal ao coração, melhorando a regulação autonômica nos SHR. Investigamos em SHR e WKY jovens (29 dias) os efeitos do T sobre parâmetros hemodinâmicos, funcionamento dos barorreceptores arteriais, tônus simpático e vagal ao coração e variabilidades, e expressão de neurônios pré-ganglionares vagais (Colina Acetil Transferase, ChAT) nos núcleos dorsal motor do vago (DMV) e ambíguo (NA). Ratos T ou sedentários (S) foram canulados nas semanas 0, 1, 2, 4 e 8, para registros funcionais e remoção dos encéfalos para a quantificação (peroxidade e estereologia). A participação dos aferentes periféricos na modulação dos efeitos do T foi avaliada com a desnervação sinoaórtica (SAD). Os efeitos do T são modulados por baro- e quimiorreceptores. O T precoce corrige a disfunção baroreflexa, reduz a hipertonia simpática, mantém parcialmente a tonicidade de neurônios colinérgicos, aumentando a modulação vagal ao coração e melhorando controle autonômico da circulação. / We hypothesized that aerobic training (T) starting at the pre-hypertensive phase reduces not only the sympathetic activity, but increases vagal outflow to the heart, thus improving autonomic cardiovascular control. We investigated in young SHR and WKY the T-induced effects on hemodynamic parameters, activation of arterial baroreceptor, sympathetic and vagal tone to the heart, and the expression of pre-ganglionic parasympathetic neurons (Choline acetyl transferase, ChAT) in the dorsal motor nucleus of the vagus (DMV) and nucleus ambiguous (NA). Rats (29 days) were T or sedentary (S) and cannulated at weeks 0, 1, 2, 4 and 8. After functional recordings, brains were harvested for quantification of neurons (peroxidase and stereology). The peripheral afferents was evaluated in sinoaortic denervation (SAD). SAD abrogated the improvement of baroreflex control and resting bradycardia in intact SHR-T. T-induced effects were modulated by arterial baro- and chemoreceptors. When started at the pre-hypertensive phase, T corrects baroreflex dysfunction, reduces sympathetic hyperactivity, maintain the tonicity of pre-ganglionic cholinergic neurons thus increasing vagal outflow to the heart and allowing a better autonomic control of the circulation.

Neurólises de plexos simpáticos têm sido utilizadas no tratamento da dor oncológica, mostrando ser um recurso terapêutico bastante eficaz e seguro. Alguns estudos apontam a utilização da neurólise de plexos simpáticos em estágios iniciais da doença por prevenir a dor e melhorar a qualidade de vida, contrariando a OMS que preconiza o uso de métodos invasivos em última instância. Em estudo prospectivo, randomizado e controlado, neurólise de plexos simpáticos realizada em estágios diferentes do tratamento da dor oncológica foi comparada com o tratamento farmacológico. Foram selecionados 60 pacientes com câncer abdominal ou pélvico e alocados em três grupos. No grupo I (precoce) os pacientes estavam em uso de AINEs e opióides fracos ou fortes (dose inferior a 90mg/dia de morfina) e reportavam dor (VAS  4) quando foram submetidos a neurólise plexo celíaco (NPC), neurólise do plexo hipogástrico superior (NPHS) ou neurólise plexo simpático lombar (NPSL) de acordo com o sítio de dor. No grupo II (tardio) a neurólise foi realizada quando a utilização de AINEs e morfina foram iguais ou superiores a 90mg/dia de morfina e VAS>4. No grupo III (controle) os pacientes fizeram uso somente de medicação analgésica. Os pacientes foram observados durante 8 semanas e avaliados quanto à intensidade da dor (VAS), consumo de opióides e qualidade de vida. Imediatamente após as neurólises e durante todo o tempo de observação, os pacientes dos grupos precoce e tardio apresentaram redução da intensidade da dor e do consumo de opióides, além disso melhora da qualidade de vida quando comparados com o grupo controle. Não houve diferenças entre os grupos precoce e tardio nestes aspectos. Efeitos adversos correlacionados com o uso de opióide, como náuseas e/ou vômitos, perda do apetite e constipação foram significativamente maiores no grupo controle. Complicações relacionadas às neurólises, tais como hipotensão e diarréia, foram transitórias e não deferiram significativamente do grupo controle. Não foram encontradas complicações sérias em nenhum dos grupos experimentais. A neurólise de plexos simpáticos foi efetiva na redução da intensidade da dor e do consumo de analgésicos e dos efeitos adversos relacionados com a administração de drogas, e na melhora da qualidade de vida dos pacientes. Embora não havendo diferenças entre os grupos precoce e tardio, os resultados apontam a necessidade de utilizar esta técnica como recurso não somente em fase terminal da doença. / Neurolytic sympathetic plexus blocks (NSPB) have been used as a quite effective and safe therapeutic resource for the treatment of cancer pain. Studies point to the use of NSPB in the early phases of the disease to prevent pain and to improve the life quality, contradicting WHO that extols the use of invasive methods ultimately. We compared the use of neurolytic plexus block in two different phases of the treatment of oncology pain with the pharmacological therapy. In prospective study, randomized and controlled, sixty patients with abdominal or pelvic oncology pain were allocated to tree groups. In group I (early block) the patients using NSAID and weak opioid or oral morphine at a dose of less than 90 mg/day and reporting pain (VAS  4) were submitted to a neurolytic celiac plexus block (NCPB), superior hypogastric plexus block (SHPB) or lumbar sympathetic ganglionic chain (LSGCB), in accordance to the site of pain. In group 2 (late block) the patients were submitted neurolysis when using NSAID and oral morphine at a dose equals to or more than 90 mg/day and VAS  4. In group 3 (control), patients were treated with pharmacological therapy only. The patients were observed for 8 weeks and appraised for the intensity of the pain (VAS), opioid consumption and quality of live. The patients of groups I and II had reduction of the intensity of the pain, opioid consumption and get better quality of live immediately after to the neurolytic and during the whole time of observation when compared with the group control. There were no significant differences between groups I and II with these aspects. Adverse effects correlated with the use of opioids, as nauseas and/or vomits, loss of the appetite and constipation were significantly larger in the group control. Neurolysis related complications such as hypotension and diarrhea, were transitory and statistically similar to these found in the control group. They were not found serious complications. The neurolysis of sympathetic plexus was shown to be effective to reduce the intensity of pain, analgesic consumption and adverse effects related to the use of opioids, and in the improvement of the quality of life. The results point to the usefulness of indicating neurolytic procedure for the management of cancer pain not only in terminal phase of the disease.

Komplette pharmakologische Unterbrechung des Baroreflexes mittels eines Ganglienblockers führt zu einer starken Zunahme der Wirkung vasoaktiver Substanzen auf den Blutdruck. Eine ähnliche Überempfindlichkeit gegenüber vasoaktiven Substanzen ist auch bei Erkrankungen zu beobachten, die mit Schädigungen des afferenten oder des efferenten Schenkels des Baroreflexes einhergehen. Variabilität der Baroreflexfunktion innerhalb der Population trägt somit in erheblichem Umfang zur Variabilität des Ansprechens auf vasoaktive Substanzen bei. Durch Vergleich der Wirkung kreislaufwirksamer Substanzen oder physiologischer Interventionen vor und während Ganglienblockade können zentrale und periphere Effekte voneinander unterschieden werden. Mit dieser Methode können Änderungen der vaskulären Sensitivität und der Pufferfunktion des Baroreflexes bei Krankheitszuständen charakterisiert werden. / Complete pharmacological interruption of the baroreflex using ganglionic blockade is associated with a profound increase in the blood pressure response to vasoactive substances. Similar hypersensitivity to vasoactive substances can be observed in disorders that involve the afferent arc or the efferent arc of the baroreflex. Therefore, interindividual variability in baroreflex function contributes substantially to the variability in the responsiveness to vasoactive substances. Comparison of the response to cardiovascular medications before and during ganglionic blockade can be used to dissect central and peripheral effects. This approach is also useful to characterize changes in vascular sensitivity and in baroreflex buffering function in diseases.

Indiana University-Purdue University Indianapolis (IUPUI) / Streptococcus mutans is a key contributor to dental caries. Smokers have increased caries, but the association between tobacco, nicotine, caries and S. mutans growth is little investigated. In the first section, seven S. mutans strains were used for screening. The minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum biofilm inhibitory concentration (MBIC) were 16 mg/ml (0.1 M), 32 mg/ml (0.2 M), and 16 mg/ml (0.1 M), respectively, for most of the S. mutans strains. Growth of planktonic S. mutans cells was significantly repressed by 2.0-8.0 mg/ml nicotine concentrations. Biofilm formation and metabolic activity of S. mutans was increased in a nicotine-dependent manner up to 16.0 mg/ml. Scanning electron microscopy (SEM) revealed higher nicotine-treated S. mutans had thicker biofilm and more spherical bacterial cells than lower concentrations of nicotine. In the second section, confocal laser scanning microscopy (CLSM) results demonstrated that both biofilm bacterial cell numbers and extracellular polysaccharide (EPS) synthesis were increased by nicotine. Glucosyltransferase (Gtf) and glucan binding protein A (GbpA) protein expression of S. mutans planktonic cells were upregulated, while GbpB protein expression of biofilm cells were downregulated by nicotine. The mRNA expression of those genes were mostly consistent with their protein results. Nicotine was not directly involved in S. mutans LDH activity. However, since it increased the total number of bacterial cells in biofilm; total LDH activity of S. mutans biofilm was increased. In the third section, a PCR-based multiple species cell counting (PCR-MSCC) method was designed to investigate the effect of nicotine on S. mutans in a ten mixed species culture. The absolute S. mutans number in mixed biofilm culture was increased but the percentage of S. mutans in the total number of bacterial cells was not changed. In conclusion, nicotine enhanced biofilm formation and biofilm metabolism of S. mutans, through stimulating S. mutans planktonic cell Gtfs and Gbps expression. This leads to more planktonic cells attaching to dental biofilm. Increased S. mutans cell numbers, in biofilms of single species or ten mixed species, resulted in higher overall LDH activity. More lactic acid may be generated and contribute to caries development in smokers.

No description available.